Trial Profile

A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALX-001 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Sponsors Allyx Therapeutics

Most Recent Events

30 Jul 2024 Planned End Date changed from 15 Jul 2024 to 15 Jul 2025.
30 Jul 2024 Planned primary completion date changed from 15 Jul 2024 to 15 Jul 2025.
11 Mar 2024 According to an Allyx Therapeutics media release, ALX-001, is ready to proceed to Phase 2 clinical development in Alzheimer's and Parkinson's disease. This announcement was made in conjunction with the presentation of positive findings from this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com